Eton Pharmaceuticals Inc 's Income per employee grew in the second quarter 2026 on a trailing twelve month basis to , the contribution of Eton Pharmaceuticals Inc 's employees, reached a new high of $ 288,364income per employee.
The Healthcare sector has seen employees of 82 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 2731, from total ranking in previous quarter at 3470.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ETON Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	288,364	-33,523	-104,568	-151,864	-93,818
ETON's Total Ranking	# 2731	# 3470	# 3232	# 3155	# 3194
Seq. Net Income Change	645.05 %	4.79 %	-	-	-

ETON Company Profile >> Back to ETON Efficiency Comparisons >> Compare ETON Net Income per Employee to its Competitors

ETON Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 83
Healthcare Sector	# 263
Overall Market	# 2731

Net Income per Employee Statistics
High	Average	Low
$ 288,364	$ -190,126	$ -635,682
(Jun 30 2026)		(Dec 31 2020)

News about Eton Pharmaceuticals Inc Income per employee

Eton Pharmaceuticals’ PKU GOLIKE Trial A Beacon of Hope for Patients and the Future of Metabolic Control

In the rapidly evolving world of biopharmaceuticals, Eton Pharmaceuticals has recently set a new benchmark with the announcement of the final readout for its groundbreaking clinical trial of PKU GOLIKE. Garnering significant clinical and statistical improvement in metabolic control during prolonged fasting in patients with phenylketonuria (PKU), this trial’s findings promise not only to enhance the lives of those affected by this genetic disorder but also to elevate awareness and foster greater adoption of its innovative treatment.Phenylketonuria, a rare genetic condition characterised by an inability to metabolise phenylalanine a compound found in many protein-based foods poses a significant challenge to affected individuals. Without stringent dietary restrictions, PKU can lead to severe cognitive deficits and neurological impairments. This is where therapies like PKU GOLIKE come into play, with the latest clinical trial demonstrating not just efficacy but robust data backing its transformative potential.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Jun 30 2026	Number of Employees Jun 30 2026
Silexion Therapeutics Corp	489,714.29	$ 6.856 Million	14
Neurocrine Biosciences Inc	352,750.00	$ 705.500 Million	2,000
Eton Pharmaceuticals Inc	288,363.64	$ 12.688 Million	44
Interpace Biosciences Inc	239,676.47	$ 24.447 Million	102
Lensar Inc	219,520.00	$ 32.928 Million	150
Standard Biotools Inc	218,267.35	$ 84.906 Million	389
Meiragtx Holdings Plc	195,858.56	$ 78.931 Million	403
Intuitive Surgical Inc	185,529.64	$ 3,157.900 Million	17,021
Transmedics Group Inc	170,973.27	$ 153.534 Million	898
Veracyte Inc	151,633.11	$ 114.483 Million	755
Johnson and Johnson	149,410.51	$ 21,037.000 Million	140,800

Date modified: 2026-09-03T11:44:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.